Accès ouvert · CC BY

Repurposing Amantadine and Memantine for COVID-19: Guanylate Kinases Might Pave the Road towards Novel SARS CoV-2 and Anti Neoplastic Therapeutics.

Article scientifique 2021 Sciences de la vie et biotechnologies › Biotechnologies (OCDE 2.9) Anglais

Résumé

New abstract: Severe and critical COVID-19 represents a medical challenge that is often lost due to the lack of efficient pharmacotherapy. Amantadine and memantine are suggested to administered first in clinical trials for selected severe and critical COVID-19 patients and a novel hypothesis that might explain their potential benefits is provided together with the other suggested mechanisms. Old abstract: Guanylate kinase 1 (GK) was suggested to play a crucial role in SARS CoV-2 replication and previous studies have suggested a role in the pathogenesis of some neoplasms. We are providing a concise strengths, weaknesses, opportunities, and threats (SWOT) analysis of this hypothesis while discussing guanylate kinase physiological function, pharmacological importance. Importantly, though GK1 role in SARS CoV-2 replication might prove valid, the available experimental inhibitors of GK 1 might not, at least for the short term, be safely used to manage COVID-19. However, we suggest assessing another potential interaction between SARS CoV-2 and the non-authentic membrane-associated guanylate kinases as we suggest this might add to consider the potential role of the NMDA antagonists amantadine and memantine in COVID-19 management for and we have recommended clinical trials for selected described COVID-19 patients. Finally, we also recommend conducting genetic, physiological, and immunological studies to explore the long-term potentials of novel GK-1 inhibitors suggesting they might eventually lead to a novel COVID-19 and cancer pharmacotherapeutics.

Citer ce document

Kelleni, M. (2021). Repurposing Amantadine and Memantine for COVID-19: Guanylate Kinases Might Pave the Road towards Novel SARS CoV-2 and Anti Neoplastic Therapeutics. https://doi.org/10.31219/osf.io/97zmy

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 05/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Auteur(s)

Statistiques

Consultations (hors robots) : 11

Téléchargements (hors robots) : 0

Méthode de comptage